利索-全球专利检索

  1. 登录
  2. 注册

搜索结果

4296 条记录 (耗时 0.018 秒)

    CAP ANALOGS HAVING AN ACYCLIC LINKER TO THE GUANINE DERIVATIVE NUCLEOBASE
    3.
    发明申请
    CAP ANALOGS HAVING AN ACYCLIC LINKER TO THE GUANINE DERIVATIVE NUCLEOBASE 审中-公开

    公开(公告)号：WO2023007019A1

    公开(公告)日：2023-02-02

    申请号：PCT/EP2022/071478

    申请日：2022-07-29

    申请人： CUREVAC SE

    发明人： SCHWARZ, Rainer Joachim

    IPC分类号： C07H19/00 ,  C07H21/00 ,  C12Q1/6806 ,  C07H19/20 ,  C07H21/02

    摘要： The present invention is inter alia concerned with (A) a compound of formula (I) as defined herein or a salt, stereoisomer, tautomer or deuterated version thereof, (B) a cap analog comprising a 5' terminal acyclonucleoside, wherein the acyclonucleoside comprises a linear unbranched structure or a linear single-branched structure instead of a ribose, wherein the 5' terminal acyclonucleoside is optionally deuterated (C) an RNA molecule comprising at least three nucleotides and comprising a 5' end of formula (III) as defined herein, wherein the 5' end is optionally deuterated (D) an RNA molecule comprising at least three nucleotides and comprising a 5' terminal acyclonucleoside, wherein the acyclonucleoside comprises a linear unbranched structure or a linear single-branched structure instead of a ribose, wherein the 5' terminal acyclonucleoside is optionally deuterated (E) an in vitro method for synthesizing an RNA molecule, (F) the RNA molecule obtained thereby, (G) compositions comprising the RNA molecule, (H) kits comprising the compound of formula (I) or the cap analog, (I) uses as well as (J) methods as outlined herein.

    ALZHEIMER'S DISEASE TREATMENT AND METHODS
    7.
    发明申请
    ALZHEIMER'S DISEASE TREATMENT AND METHODS 审中-公开

    公开(公告)号：WO2022187061A1

    公开(公告)日：2022-09-09

    申请号：PCT/US2022/017589

    申请日：2022-02-23

    申请人： BUTZLOFF, Peter

    发明人： BUTZLOFF, Peter

    IPC分类号： C01B32/152 ,  A61K31/197 ,  A61K31/198 ,  A61K33/44 ,  A61P25/28 ,  C07H21/02

    摘要： A nanoparticle composed of buckminsterfullerene bonded to glutamine, gamma amino butyric acid (GABA) and adenosine triphosphate is provided. This nanoparticle helps to regulate the energy metabolism, neural excitability, and signal transduction within the synapse and between the astrocytes and the neuronal networks of the human brain when these become dysfunctional. It is intended as a treatment for Alzheimer's disease, Lewy Body disease and other neuropathological diseases of the glutamine-glutamate-GABA cycle. Utility for remediating comorbid sexual dysfunction is promoted, as well as the antioxidant and protein oligomer disassembly properties. The adenosine triphosphate adduct provides a reversible inorganic phosphate energy storage and supply, the glutamine adduct provides a stable reservoir of this amino acid that is resistant to breakdown by reactive oxygen species, reactive nitrogen species, and astrocytes. The GABA and buckminsterfullerene functional groups are anti-oxidants to treat the most oxidatively stressed regions at neural structures.